Zevra Therapeutics (NASDAQ: ZVRA) posts $106.5M 2025 revenue; proxy items
Zevra Therapeutics announced 2025 net revenue of $106.5 million, with $87.4 million from MIPLYFFA, reporting 161 enrollment forms and 52 new patient enrollments for the therapy. The company also strengthened its financial position by selling a Rare Pediatric Disease Priority Review Voucher for $150 million, leading to the full repayment of its term loan. Zevra is preparing for its 2026 Annual Meeting on June 4, 2026, where shareholders will vote on electing directors, ratifying the auditor, and declassifying the Board.
(ZVRA) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA) using algorithmic entry frameworks. It highlights divergent sentiment readings, a challenging support level, and an exceptional risk-reward setup targeting a 20.1% gain. The piece outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones based on AI-generated signals and multi-timeframe analysis.
JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA
JPMorgan Chase & Co. significantly increased its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the third quarter, adding 410,823 shares to hold a total of 438,984 shares valued at approximately $4.18 million. Despite this institutional interest, company insiders have been net sellers, with CEO Neil McFarlane selling 91,000 shares and total insider sales amounting to 114,158 shares worth about $1.06 million in the last 90 days. Analysts maintain a "Moderate Buy" consensus rating for Zevra Therapeutics, with an average target price of $23.00, while the stock currently trades around $9.40.
Zevra Therapeutics Earnings Call Signals Profitable Turn
Zevra Therapeutics reported a significant turnaround to profitability in 2025, driven by strong MIPLYFFA sales, which contributed 82% of its full-year revenue. The company achieved $83.2 million in net income, reversing a $105.5 million loss from the previous year, and ended 2025 with $238.9 million in cash. While facing challenges such as quarterly revenue volatility and slow progress in a Phase III trial for celiprolol, Zevra emphasized its solid financial position, regulatory advancements in Europe, and success in securing U.S. market access for MIPLYFFA.
Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA
Hennion & Walsh Asset Management Inc. invested $1.25 million in Zevra Therapeutics, Inc. (NASDAQ:ZVRA), acquiring 139,591 shares in the 4th quarter of 202X. This investment constitutes about 0.25% of Zevra Therapeutics, with institutional investors now holding 35.03% of the company's stock. The article also notes recent insider selling by the CEO and another insider, alongside a "Moderate Buy" analyst consensus with an average price target of $23.00, significantly above the current trading price of around $9.40.
Vanguard realignment: affiliates to report ZVRA holdings separately (ZVRA)
The Vanguard Group has filed an amended Schedule 13G/A for Zevra Therapeutics (ZVRA), reporting 0 shares and 0% beneficial ownership. This change is due to an internal realignment at Vanguard, where certain subsidiaries will now report their holdings separately, citing SEC Release No. 34-39538. The filing clarifies that this is an administrative reporting change and not a modification to Zevra Therapeutics' outstanding shares or dilution.
John B Bode At Zevra Therapeutics Executes Options Exercise, Realizing $326K
John B. Bode, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 78,400 shares valued at $326,928, as reported in a recent SEC filing. The company shows strong revenue growth of 183.36% and favorable profitability metrics like a high gross margin and above-average EPS. While its debt-to-equity ratio is higher than the industry average, its market capitalization and EV/EBITDA ratio suggest potential undervaluation.
How (ZVRA) Movements Inform Risk Allocation Models
This article analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA) using AI models, highlighting conflicting sentiment across different time horizons and a mid-channel oscillation pattern. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis indicating support and resistance levels. The analysis aims to help traders optimize position sizing and minimize drawdown risk by leveraging institutional-grade AI signals.
Zevra Therapeutics announced that, in accordance with Nasdaq Listing Rule 5635(C)(4), it has granted an inducement equity award to the company's new Chief Financial Officer.
Zevra Therapeutics has granted an inducement equity award to its new Chief Financial Officer, in compliance with Nasdaq Listing Rule 5635(C)(4). This award is part of the company's incentive plan for new employees and adheres to regulatory requirements. The announcement was made by 老虎证券 and is not an investment recommendation.
New Zevra finance chief gets a 300,000-share stock option
Zevra Therapeutics granted its new CFO, Justin Renz, an inducement equity award of 300,000 stock options. The options have an exercise price of $9.55, a 10-year term, and will vest over four years, aligning Renz's interests with those of the shareholders. This award was approved under Nasdaq Rule 5635(c)(4) as a material inducement for his employment.
GeneDx (WGS), Zevra Therapeutics (ZVRA) partner to launch sponsored genetic testing program for NPC
GeneDx (WGS) and Zevra Therapeutics (ZVRA) have announced a partnership to launch a sponsored genetic testing program for Niemann-Pick disease type C (NPC). This initiative aims to improve early diagnosis of NPC, a rare and progressive neurodegenerative disorder, by offering no-cost genetic testing to individuals suspected of having the condition. The collaboration highlights the growing importance of genetic testing in identifying rare diseases and facilitating timely treatment.
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics announced that it has granted an equity inducement award to its new Chief Financial Officer, Justin Renz, as of March 18, 2026. This award, approved by the Compensation Committee and made under Nasdaq Rule 5635(c)(4), includes an option to purchase 300,000 shares of common stock with an exercise price of $9.55 per share. The option vests over four years, subject to Mr. Renz's continued employment.
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics announced an equity inducement award for its new Chief Financial Officer, Justin Renz, consisting of an option to purchase 300,000 shares of common stock. The award, approved by the Compensation Committee, is a material inducement for his employment and vests over four years. This grant was made in accordance with Nasdaq Rule 5635(c)(4).
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Zevra Therapeutics announced the sale of its entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, to Commave Therapeutics SA for $50 million. This agreement also resolves a 2024 litigation initiated by Commave against Zevra. The company stated this transaction allows them to focus on their mission of providing therapies for rare diseases, after having also repaid its $63 million term loan, resulting in a debt-free balance sheet.
Zevra Therapeutics (ZVRA) CFO Justin Renz files insider ownership report
Zevra Therapeutics CFO Justin A. Renz has filed an initial statement of beneficial ownership (Form 3) with the SEC. The filing indicates Renz's position as CFO but reports no beneficial ownership of non-derivative securities and no derivative positions or transactions at the time of the report. This Form 3 primarily serves to establish Renz as an insider reporting person for future transactions.
CFO at Zevra (NASDAQ: ZVRA) receives 300,000-share option grant
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) CFO Justin A. Renz was granted stock options to purchase 300,000 shares of common stock. The options have an exercise price of $9.55, matching the March 18, 2026 closing price, and will vest in four equal annual installments starting one year from the grant date, subject to continued service. The award was made under Zevra’s 2023 Employment Inducement Award Plan and includes accelerated vesting provisions in case of a change of control or certain employment terminations.
$Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics announced an equity inducement award to its new Chief Financial Officer, Justin Renz, as a material inducement for his acceptance of employment. This grant, approved by the Compensation Committee and in accordance with Nasdaq Rule 5635(c)(4), includes an option to purchase 300,000 shares of common stock at an exercise price of $9.55, vesting over four years. Zevra Therapeutics is a commercial-stage company focused on providing therapies for rare diseases.
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Zevra Therapeutics has sold its entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, to Commave Therapeutics SA for $50 million. This transaction also included the full repayment of Zevra's $63 million term loan, making the company debt-free, and resolved prior litigation between the two companies. Zevra will now focus on its rare disease franchise.
Zevra Shares Jump After Selling SDX Portfolio For $50M
Zevra Therapeutics' shares jumped after the company announced the sale of its serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, to Commave Therapeutics SA for $50 million. This agreement also resolves previous litigation between the two companies. Furthermore, Zevra repaid its $63 million term loan, resulting in a debt-free balance sheet and increased financial flexibility.
Zevra (Nasdaq: ZVRA) sells SDX portfolio for $50M and repays $63M loan
Zevra Therapeutics has sold its entire SDX portfolio, including AZSTARYS® and KP1077, to Commave Therapeutics for $50 million. This transaction also resolves pending litigation and terminates a 2019 license agreement between the companies. Additionally, Zevra repaid its outstanding $63 million senior secured term loan, resulting in a debt-free balance sheet and increased financial flexibility.
Zevra Therapeutics Sells Sdx Portfolio To Commave Therapeutics For $50 Million
Zevra Therapeutics has sold its SDX portfolio to Commave Therapeutics for $50 million. This transaction was reported by Reuters and is categorized under mergers and acquisitions, impacting US stocks.
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook
BTIG has initiated coverage on Zevra Therapeutics (NASDAQ:ZVRA) with a Buy rating and a $23 price target, citing the Miplyffa outlook and potential for significant upside. The firm anticipates expansion in the U.S. NPC patient population, EU approval for arimoclomol, and an extended exclusivity window for Miplyffa. This positive outlook is further supported by Zevra's strong Q4 2025 financial results and Guggenheim's recent price target increase to $23.00.
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Zevra Therapeutics has sold its entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, to Commave Therapeutics SA for $50 million. This agreement also resolves a lawsuit previously initiated by Commave against Zevra in Delaware Chancery Court. Zevra repaid its $63 million term loan in full, achieving a debt-free balance sheet to support its focus on rare disease therapies.
Zevra Therapeutics, Inc. $ZVRA Shares Bought by Kingdon Capital Management L.L.C.
Kingdon Capital Management L.L.C. significantly increased its stake in Zevra Therapeutics (NASDAQ:ZVRA) by 44.4% in the third quarter, now owning 650,000 shares valued at $6.18 million. Institutional ownership stands at around 35%, with other firms like Bank of America and Cantor Fitzgerald also increasing their positions. Despite recent insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $23.00.
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Zevra Therapeutics has announced an agreement to sell its entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, to Commave Therapeutics SA for $50 million. This sale also resolves a lawsuit previously initiated by Commave against Zevra in Delaware Chancery Court. The transaction leaves Zevra Therapeutics with a debt-free balance sheet, allowing them to focus on therapies for rare diseases.
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Zevra Therapeutics has sold its serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, to Commave Therapeutics SA for $50 million. This agreement resolves a lawsuit initiated by Commave in 2024 concerning a 2019 license agreement. Zevra stated that this transaction allows them to focus on their mission of providing therapies for rare diseases and they are now debt-free.
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress
Zevra Therapeutics (ZVRA) is undervalued according to analysts, benefiting from its Q4 2025 earnings, profitability, and the commercial progress of MIPLYFFA. Despite a recent share price dip, the company shows strong momentum due to its rare disease focus, FDA approval of MIPLYFFA, and a fortified balance sheet from a Priority Review Voucher sale. The market has yet to fully price in the high-margin, recurring revenue potential of its rare disease monopoly, suggesting significant upside based on an estimated fair value of $26.89.
Zevra Therapeutics (NASDAQ:ZVRA) Cut to "Hold" at Wall Street Zen
Zevra Therapeutics (NASDAQ:ZVRA) was downgraded from "buy" to "hold" by Wall Street Zen, although the consensus among eight analysts remains a "Moderate Buy" with an average price target of $23.00. The stock opened at $9.98, trading significantly below its target, with a market capitalization of $585.93 million and a P/E ratio of 7.50. Insider selling of over 114,000 shares totaling $1.06 million was noted in the last three months, while institutional investors hold approximately 35% of the stock.
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress
Zevra Therapeutics (ZVRA) has reported better-than-expected Q4 and full-year 2025 earnings, achieving profitability driven by MIPLYFFA sales and strategic partnerships, including GeneDx. Despite a recent stock pullback to US$10.19, the company holds a 90-day share price return of 22.3% and a 3-year total shareholder return above 100%. Analysts currently have a price target of US$22.75, with the market narrative suggesting a fair value of $26.89, indicating the stock is undervalued given its transition to commercial sales and its rare disease monopoly.
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA)
This article provides an overview of ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) stock, including its current price, performance, and key statistics. It details technical and fundamental analysis ratings from ChartMill, recent earnings reports, analyst forecasts, and company information. The stock was trading at $9.98 USD, down 2.01% on the day, but showed significant gains over longer periods.
Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case
Zevra Therapeutics (ZVRA) reported a significant profit swing to US$77.6 million trailing twelve-month net income by Q4 2025, up from a US$105.5 million net loss in Q4 2024. While this supports a bullish outlook for its rare disease portfolio, the analysis highlights that a large portion of this profit is non-cash and quarterly results have been uneven, raising questions about the durability of the reported earnings. Despite a low P/E ratio compared to peers and a high DCF fair value, cautious investors are advised to consider the substantial non-cash components and volatility in earnings.
Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case
Zevra Therapeutics (ZVRA) reported a significant profit swing in FY 2025, moving from a US$105.5 million net loss in Q4 2024 to a US$77.6 million net income by Q4 2025, with total revenue reaching US$106.5 million. While this supports a bullish outlook for its rare disease portfolio, the presence of large non-cash items and uneven quarterly results raise questions about the durability and consistency of these profits. The company's valuation metrics, including a P/E of 8.4x against a fair value of US$72.87, suggest it may be undervalued, but cautious investors are scrutinizing the quality of earnings due to non-cash components and volatility.
Why Is Zevra Therapeutics Stock Trading Higher Today?
Zevra Therapeutics (NASDAQ: ZVRA) shares rose on Tuesday after the company announced a new partnership with GeneDx Holdings Corp. (NASDAQ: WGS) to expand genetic testing for Niemann-Pick Disease type C (NPC). This collaboration aims to improve diagnosis and treatment options for NPC patients. The stock also benefited from Zevra's strong fourth-quarter results, where it beat analyst estimates for both earnings and sales.
Why Zevra Therapeutics Stock Zoomed 21% Higher Today
Zevra Therapeutics (NASDAQ: ZVRA) saw its stock jump 21% after reporting strong fourth-quarter earnings for 2025. The company posted net revenue of over $34 million, a 44% year-over-year increase, and a net profit of $12.2 million, significantly beating analyst expectations. Much of this success is attributed to the expanded availability and sales growth of its Niemann-Pick disease treatment, Miplyffa, which is also under review for marketing authorization in the European Union.
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
GeneDx announced a new genetic testing program with Zevra Therapeutics to expand access to its ExomeDx™ test for patients suspected of having Niemann-Pick disease type C (NPC). This program aims to accelerate accurate diagnoses, guide clinical decision-making, and contribute de-identified data to the GeneDx Infinity™ dataset to improve understanding and treatment of NPC. The initiative underscores the growing importance of timely genetic diagnosis for this rare, progressive, and often underdiagnosed condition.
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
GeneDx has announced a new genetic testing program in partnership with Zevra Therapeutics to support patients with suspected Niemann-Pick Disease Type C (NPC). This program will expand access to GeneDx’s ExomeDx™ test, aiming to provide faster and more accurate diagnoses for NPC, a rare and often underdiagnosed inherited condition. Zevra Therapeutics will financially support the program, enabling eligible U.S. patients to receive the ExomeDx test at no charge and receive results within approximately three weeks.
Guggenheim raises Zevra Therapeutics stock price target to $23
Guggenheim has increased its price target for Zevra Therapeutics (NASDAQ:ZVRA) to $23 from $22, maintaining a Buy rating due to the strong performance of Miplyffa and significant revenue growth. The company also reported impressive Q4 2025 financial results, exceeding EPS and revenue expectations. Zevra's expansion into Europe and growth in its expanded access program support analyst confidence in the stock.
Zevra Therapeutics price target raised to $23 from $22 at Guggenheim
Guggenheim has increased its price target for Zevra Therapeutics (ZVRA) from $22 to $23, maintaining a Buy rating on the shares. The firm based its decision on the strong performance of Miplyffa's launch, noting an acceleration in FY25 results and anticipating continued steady growth as the product expands its U.S. market penetration and maintains high retention rates.
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Zevra Therapeutics Inc. (NASDAQ: ZVRA) shares significantly increased in pre-market trading after reporting better-than-expected fourth-quarter financial results, surpassing analyst estimates for both earnings and sales. The article also lists other stocks experiencing movement in pre-market trading, including both gainers like BioRestorative Therapies Inc. (NASDAQ: BRTX) and losers such as Arq Inc. (NASDAQ: ARQ) and FreightCar America Inc. (NASDAQ: RAIL).
Profit Swing, MIPLYFFA Uptake and New CFO Might Change The Case For Investing In Zevra Therapeutics (ZVRA)
Zevra Therapeutics (ZVRA) reported strong 2025 results, including a swing to profitability and increased sales. The company's focus on its ultra-rare disease drug, MIPLYFFA, and the appointment of a new CFO are key to its investment narrative, though dependence on a single asset and a small addressable market present challenges. Forecasts suggest significant revenue and earnings growth by 2028, with a potential 155% upside to its current price.
Zevra Therapeutics Stock Pre-Market (+17%): Reports Massive Q4 EPS Beat
Zevra Therapeutics' stock saw a significant pre-market surge of 17% following the announcement of a massive Q4 EPS beat. The article headline indicates strong positive sentiment from investors regarding the company's recent financial performance. Further details within the article would elaborate on the specifics of the earnings report.
Zevra Therapeutics: Fourth Quarter Earnings Overview
Zevra Therapeutics reported a net profit of $12.2 million in the fourth quarter, with earnings of $0.19 per share, or $1.16 per share after asset impairment adjustments. The company's revenue for the quarter was $34.1 million, exceeding analyst expectations of $27.9 million. For the full year, Zevra Therapeutics achieved a total profit of $83.2 million and annual revenue of $106.5 million.
Zevra Therapeutics: Q4 Earnings Snapshot
Zevra Therapeutics, Inc. reported a net income of $12.2 million in its fourth quarter, translating to 19 cents per share, or $1.16 per share when adjusted for asset impairment costs. The specialty pharmaceutical company exceeded Street forecasts with revenues of $34.1 million for the quarter and recorded annual profits of $83.2 million on revenues of $106.5 million.
Zevra Therapeutics: Q4 Earnings Snapshot
Zevra Therapeutics (ZVRA) reported a net income of $12.2 million in its fourth quarter, translating to $0.19 per share, or an adjusted $1.16 per share. The company's revenue for the quarter was $34.1 million, surpassing analyst expectations of $27.9 million. For the full year, Zevra Therapeutics posted a profit of $83.2 million ($1.35 per share) and reported total revenue of $106.5 million.
Zevra Therapeutics: Q4 Earnings Snapshot
Zevra Therapeutics, Inc. reported a net income of $12.2 million in its fourth quarter, translating to 19 cents per share. After adjusting for asset impairment costs, earnings per share reached $1.16. The specialty pharmaceutical company exceeded Street forecasts with fourth-quarter revenue of $34.1 million and reported a full-year profit of $83.2 million on $106.5 million in revenue.
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
Zevra Therapeutics has announced the appointment of Justin Renz as its new Chief Financial Officer, effective March 9, 2026. Renz brings over 25 years of biopharmaceutical financial leadership experience, including expertise in capital markets and commercial-stage operations. This appointment is expected to strengthen Zevra's financial foundation as it continues to advance its rare disease therapies.
Zevra Therapeutics Appoints New CFO
Zevra Therapeutics has announced the appointment of Justin Renz as its new Chief Financial Officer, effective March 9, 2026. Renz brings extensive financial strategy and biopharmaceutical industry experience, including previous CFO and COO roles at Ardelyx and Correvio Pharma, where he successfully commercialized several innovative medicines. His proven track record in financial management and product launches is expected to strengthen Zevra's financial health and market competitiveness.
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
Zevra Therapeutics has announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026. Renz brings over 25 years of financial leadership experience in the biopharmaceutical industry, with a strong background in capital markets, strategic transactions, and commercial operations. His appointment is expected to bolster Zevra's financial foundation and support its strategic goal of becoming a leading rare disease company.
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
Zevra Therapeutics has announced the appointment of Justin Renz as its new Chief Financial Officer, effective March 9, 2026. Renz brings over 25 years of financial leadership experience in the biopharmaceutical industry, with expertise in capital markets, strategic transactions, and commercial-stage operations. His appointment is expected to strengthen Zevra's financial foundation as the company aims to become a leading rare disease company.
25-year biopharma finance leader Justin Renz joins Zevra as CFO
Zevra Therapeutics has appointed Justin Renz as Chief Financial Officer, effective March 9, 2026. Renz brings over 25 years of biopharmaceutical financial leadership, including expertise in capital markets and commercial launches, and holds multiple advanced degrees and CPA credentials. This hire aims to strengthen Zevra's financial foundation and accelerate the company's rare disease strategy.
